List view / Grid view

Articles

C is for Cancer Drugs Fund

16 November 2016 | By Niamh Louise Marriott, Digital Content Producer

C is for Cancer Drugs Fund - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest on the Cancer Drugs Fund

B is for Biosimilars

15 November 2016 | By Niamh Louise Marriott, Digital Content Producer

B is for Biosimilar - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the subject of biosimilars.

A is for Antibiotics

14 November 2016 | By Niamh Louise Marriott, Digital Content Producer

A is for Antibiotics - the first instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the subject of antibiotics.

Democratising the Data-Driven Medicine revolution

7 November 2016 | By Jurgi Camblong, CEO and co-founder of Sophia Genetics

Sophia Genetics' CEO Jurgi Camblong says genomic data can now diagnose and tailor individual treatments but how do we democratise Data-Driven Medicine?

Issue #5 2016 – Digital edition

20 October 2016 | By European Pharmaceutical Review

In this issue: Biosimilars, Informatics, Ingredients, PAT, HPLC, Microbiology, Product Showcase, Regulation, and much more...

Biosimilars: litigation outlook

20 October 2016 | By

In the Foreword article contributed by Consultant David P. Elder in Issue 3, 2016 of European Pharmaceutical Review, entitled ‘Biosimilars: future prospects’, Dr Elder concluded that it is likely that biosimilars will become increasingly established in both Europe and the United States and that in addition to proteins and peptides,…

At-line swabbing analysis as a process analytical tool

20 October 2016 | By Adeyinka Aina and Chris Edlin, Pharmaceutical Manufacturing Technology Centre

Swabbing is a technique commonly used during pharmaceutical cleaning protocols to ensure that the cleaning process meets both safety and regulatory requirements; this allows for the cleaning process to be subsequently verified and validated1-7.